CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will also be featured at 2026 American Academy of Neurology Annual Meeting later this month; findings demonstrate neflamapimod’s potential positive impact on basal forebrain atrophy and functional connectivity Dementia with Lewy bodies (DLB) is the second most common progressive dementia, affecting millions worldwide, and has no approved treatments in the United States or European Union BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, will present key aspects of its neflamapimod clinical program today at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA, including updates on the program’s clinical findings, global regulatory alig
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
- CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-PathologyGlobeNewswire
- CervoMed (CRVO) had its price target lowered by Roth Mkm from $19.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- CervoMed (CRVO) had its price target raised by Chardan Capital from $15.00 to $21.00. They now have a "buy" rating on the stock.MarketBeat
- CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesGlobeNewswire
CRVO
Earnings
- 11/7/25 - Miss
CRVO
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/7/26 - Form 8-K
- 3/23/26 - Form 8-K
- CRVO's page on the SEC website